Results 261 to 270 of about 43,876 (313)
Some of the next articles are maybe not open access.
Drugs & Aging, 2003
Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.
David R Goldsmith, Lesley J. Scott
openaire +3 more sources
Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.
David R Goldsmith, Lesley J. Scott
openaire +3 more sources
Donepezil for severe Alzheimer's disease [PDF]
The Lancet, 2006 1conclude that donepezil improves cognition and pre serves function in nursing home patients with severe Alzheimer’s disease. Some points should be discussed before accepting this conclusion. Although Winblad and colleagues mention that a CT or MRI scan consistent with Alzheimer’s disease was required for entry into the study, such imaging is insuffi ...
Yujiro Kida, Yujiro Kida, Tetsuji Sato
openaire +5 more sources
An Update on the Routes for the Delivery of Donepezil
Molecular Pharmaceutics, 2021Dementia is a significant public health problem in the 21st century. Alzheimer's disease (AD) is an essential factor in dementia. Currently, the drugs used for the treatment of AD are mainly acetylcholine inhibitors (AChEIs). As an AChEI, donepezil (DP) can improve patients' cognitive ability with low side effects and has been accepted by most patients
Ze Qiang Zhao +4 more
openaire +3 more sources
Drugs of Today, 1998
Donepezil is a highly selective, long-acting acetylcholinesterase inhibitor which has been approved in numerous countries for the treatment of Alzheimer's disease. Donepezil increases the levels of acetylcholine in the brain of patients with Alzheimer's disease and presumably corrects some dysfunction associated with loss of cells in the basal ...
openaire +2 more sources
Donepezil is a highly selective, long-acting acetylcholinesterase inhibitor which has been approved in numerous countries for the treatment of Alzheimer's disease. Donepezil increases the levels of acetylcholine in the brain of patients with Alzheimer's disease and presumably corrects some dysfunction associated with loss of cells in the basal ...
openaire +2 more sources
Hypnopompic hallucinations with donepezil
Journal of Psychopharmacology, 2000A case of hypnopompic hallucinations associated with donepezil is described. Electroencephalogram (EEG) and sleep EEG changes are common in Alzheimers Disease and acetylcholinesterase inhibitor drugs can affect rapid eye movement sleep and alertness. The importance of assessing sleep in patients treated with these drugs is discussed.
R. Gray, G. A. Yorston
openaire +3 more sources
2010
Publisher Summary Donepezil hydrochloride is a white powder and is freely soluble in water and in chloroform, sparingly soluble in glacial acetic acid and in ethanol, slightly soluble in acetonitrile, very slightly soluble in ethyl acetate, and insoluble in n-hexane. Donepezil hydrochloride (E2020) is the second drug approved by the United States food
Gamal A. E. Mostafa, Yousif A. Asiri
openaire +3 more sources
Publisher Summary Donepezil hydrochloride is a white powder and is freely soluble in water and in chloroform, sparingly soluble in glacial acetic acid and in ethanol, slightly soluble in acetonitrile, very slightly soluble in ethyl acetate, and insoluble in n-hexane. Donepezil hydrochloride (E2020) is the second drug approved by the United States food
Gamal A. E. Mostafa, Yousif A. Asiri
openaire +3 more sources
Journal of Chemical Information and Modeling, 2020
Alzheimer's disorder is one of the most common world-wide health problems and its prevalence continues to increase thereby straining the healthcare budgets of both developed and developing countries. We report herein a new donepezil-like natural compound
B. A. Akhoon +7 more
semanticscholar +1 more source
Alzheimer's disorder is one of the most common world-wide health problems and its prevalence continues to increase thereby straining the healthcare budgets of both developed and developing countries. We report herein a new donepezil-like natural compound
B. A. Akhoon +7 more
semanticscholar +1 more source
Journal of Psychopharmacology, 2020
Background: A potent acetylcholinesterase inhibitor, donepezil is a cognitive enhancer clinically used to treat neurodegenerative diseases. However, its complete pharmacological profile beyond cognition remains unclear.
A. C. Giacomini +8 more
semanticscholar +1 more source
Background: A potent acetylcholinesterase inhibitor, donepezil is a cognitive enhancer clinically used to treat neurodegenerative diseases. However, its complete pharmacological profile beyond cognition remains unclear.
A. C. Giacomini +8 more
semanticscholar +1 more source
Expert Opinion on Pharmacotherapy, 2007
Donepezil hydrochloride is the most widely prescribed drug for Alzheimer's disease (AD). The main mechanism of action through which it influences cognition and function is presumed to be the inhibition of acetylcholinesterase enzyme in the brain; however, donepezil may also impact the pathophysiology of AD at several other points.
openaire +2 more sources
Donepezil hydrochloride is the most widely prescribed drug for Alzheimer's disease (AD). The main mechanism of action through which it influences cognition and function is presumed to be the inhibition of acetylcholinesterase enzyme in the brain; however, donepezil may also impact the pathophysiology of AD at several other points.
openaire +2 more sources
Expert Opinion on Drug Metabolism & Toxicology, 2005
Donepezil is a selective acetylcholinesterase inhibitor that is widely prescribed for Alzheimer's disease (AD). It has been shown to be of benefit in mild, moderate and severe stages of AD, vascular dementia and dementia associated with Parkinson's disease. Donepezil is absorbed slowly, but completely, from the gut, reaching peak plasma levels in 3-4 h
openaire +3 more sources
Donepezil is a selective acetylcholinesterase inhibitor that is widely prescribed for Alzheimer's disease (AD). It has been shown to be of benefit in mild, moderate and severe stages of AD, vascular dementia and dementia associated with Parkinson's disease. Donepezil is absorbed slowly, but completely, from the gut, reaching peak plasma levels in 3-4 h
openaire +3 more sources